Actively Recruiting
Study of SC-102 in Patients With Advanced Solid Tumors
Led by Tianjin ConjuStar Biologics Co., Ltd. · Updated on 2025-07-29
120
Participants Needed
1
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors
CONDITIONS
Official Title
Study of SC-102 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign the informed consent form
- Aged 18 to 75 years at the time of consent, any gender
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Life expectancy of at least 3 months as assessed by the investigator
- Women and men of childbearing potential agree to use effective contraception during the study
- Willing and able to follow the study protocol and procedures
- Acceptable kidney, liver, blood, and coagulation function
- Measurable disease based on RECIST v1.1 criteria
- Histologically confirmed metastatic recurrent malignant solid tumors with no remaining standard treatment options
- EphA2 expression confirmation required prior to enrollment only for dose expansion study participants
You will not qualify if you...
- History of other cancers within 3 years prior to consent, except certain cured skin, cervical, thyroid, or breast cancers with long disease-free survival
- Anticancer treatment, including experimental therapies, within 4 weeks before first dose
- Radiotherapy to more than 30% of bone marrow or extensive radiotherapy within 4 weeks, or local radiotherapy within 7 days before first dose
- Uncontrolled brain metastases
- Existing treatment-related toxicity Grade 2 or higher (except some stable conditions)
- Sensory or motor neuropathy Grade 2 or higher
- Major surgery within 4 weeks prior to first dose
- History or suspicion of interstitial lung disease that cannot be ruled out by imaging
- Serious skin diseases or severe skin reactions during previous cancer treatments
- Active infection needing systemic treatment within 14 days before first dose
- Thromboembolic events or bleeding disorders within 3 months before first dose
- Positive virus serology tests
- Serious cardiovascular or cerebrovascular diseases
- Treatment with strong CYP3A4 inhibitors or inducers within 2 weeks before first dose
- Known allergy to any ingredients of SC-102
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Actively Recruiting
Research Team
J
Jing Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here